Italy publishes new guidelines on pricing and reimbursement of generics and biosimilars

Home/Guidelines | Posted 29/01/2021 post-comment0 Post your comment

The Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) announced on 30 December 2020 that it had published new guidelines for the pricing and reimbursement of medicines, which include a new streamlined procedure for generics and biosimilars.

Meds Cost Euros 1 V13L06

The new guidelines were produced following public consultation:

Guidelines for compiling the dossier in support of the application refundability and price of a medicinal pursuant to D.M. 2 August 2019
(Linee guida per la compilazione del dossier a supporto della domanda di rimborsabilità e prezzo di un medicinale ai sensi del D.M. 2 agosto 2019)
Date: Version 1.0 2020
https://www.aifa.gov.it/documents/20142/1283800/Linee_guida_dossier_domanda_rimborsabilita.pdf/8249e3d6-b2fc-915d-a211-02abafb8aa6d

For generics and biosimilars the new simplified procedure applies to generics and biosimilars that have the same packaging as the originator in terms of dosage units, amount of active ingredient, pharmaceutical form, route of administration and delivery method. It does not apply to generics and biosimilars with additional indications to those of the originator, or with different packaging (dosage units, dosage and route of administration).

The new procedure simplifies the procedure for negotiation of price and class of reimbursement. This means that for generics and biosimilars whose reference products are considered essential drugs for chronic and serious diseases (Class A) or require a hospital setting and specialist supervision (Class H) and that are 100% reimbursed by the Italian National Health Service (NHS), there will be a gradual reduction in the involvement of the AIFA’s Technical Scientific Committee (Comissione Technico Scientifica) and Pricing and Reimbursement Committee (Comitato Prezzi e Rimborso).

With respect to generics and biosimilars whose reference products are considered Class C drugs, i.e. over-the-counter products, will allow the new medicine to follow the authorization phase, without any negotiation with the Health Technology Assessment and AIFA Committees.

In addition to these changes, the AIFA has also introduced specific rules for cases where the patent expiry date of the active ingredient is more than one year compared to the date of submission of the reimbursement application.

The guidelines will come into effect from 1 March 2021 in order to provide stakeholders with a suitable transition period for the compilation of new dossiers. This date also takes into consideration possible pricing and reimbursement applications already at an advanced stage and that were submitted in accordance with the previous model.

Related article
Biosimilars policies in Italy

LATIN AMERICAN FORUM – Coming soon!

To further enhance the objectives of GaBI in sharing information and knowledge that ensure policies supportive of safe biosimilars use, we are pleased to announce that we will be launching a new section on GaBI Online and GaBI Journal, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America.

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

 

LATIN AMERICAN FORUM – Próximamente!

Para fomentar los objetivos de GaBI sobre la difusión de información y conocimiento sobre las políticas de apoyo que garantizan el uso seguro de medicamentos biosimilares, nos complace anunciar el lanzamiento de una nueva sección en GaBI Online y GaBI Journal, el ‘Latin American Forum’ (en español), que presentará las últimas noticias y actualizaciones en investigación y desarrollo sobre medicamentos genéricos y biosimilares en Latinoamérica.

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

Source: AIFA

comment icon Comments (0)
Post your comment
Related content
WHO guidelines on pharmaceutical pricing policies
Pay for Delay DrugsMoneyGeneric V13F21
Home/Guidelines Posted 24/09/2021
Mexico introduces new decree on health regulation
Regulation-V13H16
Home/Guidelines Posted 27/08/2021
Draft decree for prescribing generics in Costa Rica
46 MD001580
Home/Guidelines Posted 09/07/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010